MAGE was a Multicenter, single-Arm, observational 6-month (plus 6-month extension) study that aimed to assess treatment satisfaction, efficacy, and safety of insulin Glargine 300 U/mL (Gla-300) in people with type 2 diabetes (T2DM) receiving basal-bolus insulin in a rEal-world setting.
Materials and methods
Participants were at least 18 years old, with T2DM for more than 1 year, HbA1c 7.0–10.0%. The primary endpoint was change in Diabetes Treatment Satisfaction Questionnaire status version (DTSQs) total score (baseline to month 6). Secondary endpoints included reasons for starting Gla-300, changes in the DTSQ change version (DTSQc) total score, Hypoglycemia Fear Survey-II (HFS-II) total behavior and worry scores at months 6 and 12, HbA1c changes at months 3, 6, 9, and 12, and safety.
Results
MAGE included 87 adults (mean T2DM duration 17 years). The primary endpoint of DTSQs mean (standard deviation) total score improvement at month 6 was achieved (2.80 [5.46] points; p < 0.0001). The main reasons for Gla-300 initiation were to decrease HbA1c (89.7% of participants) and reduce the number of hypoglycemic events (35.6% of participants). Significant improvements were observed in the DTSQc total score and perceived hyperglycemia/hypoglycemia (baseline to month 6, p < 0.05). Significant changes in HFS-II behavior, worry, and total scores at 6 and 12 months were also observed (p < 0.05). There were no statistically significant changes in HbA1c. Safety outcomes, including hypoglycemia, were comparable to previously reported trials.
Conclusions
The MAGE study indicates that Gla-300, as part of a basal-bolus regimen, results in improved treatment satisfaction and reduced hypoglycemia fear in people with advanced T2DM.
Improved treatment satisfaction is an important factor in the treatment of type 2 diabetes (T2DM) and is required to gain better treatment adherence
The second-generation basal insulin analogue insulin glargine 300 U/mL (Gla-300) provides a longer duration of action and more stable pharmacodynamic profile than the first-generation analogue, Gla-100
The primary objective and endpoint of the real-world observational MAGE study was to assess treatment satisfaction when switching to Gla-300 in people with T2DM receiving basal-bolus insulin
What was learned from the study?
People with advanced T2DM who switched to Gla-300 treatment had a significant improvement in treatment satisfaction and reduced hypoglycemia fear, without a reduction in HbA1c
The improved treatment satisfaction observed with Gla-300 in people with T2DM may improve treatment adherence, thus contributing to long-term stable glucose control
Introduction
Improving treatment satisfaction and safety are important for treating type 2 diabetes (T2DM) and are required to gain better treatment adherence, thereby improving long-term outcomes [1]. Poor adherence to insulin treatment results from many factors, including a busy lifestyle, travels, stress or psychosocial issues, skipped meals, and treatment-associated burden such as the number of injections, flexibility in injection time, regimen complexity, and hypoglycemia [2]. Hypoglycemia is associated with reduced quality-of-life (QoL) due to its inherent stressful nature and worries regarding individual psychosocial consequences [3]. Hypoglycemia itself also often results in poor treatment adherence [4].
Anzeige
Second-generation long-acting basal insulin (BI) analogues, including insulin glargine 300 U/mL (Gla-300), provide a longer duration of action and even more stable pharmacokinetic/pharmacodynamic profiles than the first-generation BI analogue, Gla-100 [5, 6]. The EDITION treat-to-target randomized controlled trial (RCT) program compared Gla-300 with Gla-100 in populations with type 1 and T2DM [7‐14]. EDITION 1, which included people with T2DM treated with a basal-bolus treatment regimen, showed that Gla-300 provided similar glycemic control after 6 months, but with significantly less nocturnal hypoglycemia compared with Gla-100, and a more sustained HbA1c reduction for Gla-300 at 12 months [8, 9]. Gla-300 may also reduce insulin treatment burden compared with Gla-100, as it allows more flexibility in the timing of injections, requires a reduced volume of injected insulin, and results in smaller glycemic excursions [15, 16].
Most studies of BI analogues are not specifically designed to evaluate treatment satisfaction. Therefore, MAGE aimed to assess treatment satisfaction, efficacy, and safety of Gla-300 in people with T2DM receiving basal-bolus insulin in a real-world setting, and is distinct from other real-world studies, as treatment satisfaction was the primary endpoint.
Methods
Study Design
MAGE (a 6-month Multicenter, prospective, single-Arm, observational study with a 6-month extension period, evaluated treatment satisfaction, efficacy and safety of insulin Glargine 300 U/mL in people with T2DM receiving basal-bolus insulin in a rEal-world setting), was conducted in second-line diabetes clinics in Belgium. MAGE was performed in accordance with the principles of the 18th World Medical Assembly (Declaration of Helsinki, 1964) and all subsequent amendments, the European guidelines for Good Epidemiology Practice, and complied with local regulatory requirements [17, 18]. All participants signed an informed consent form before taking part in the study and study extension.
Study Population
Participants were at least 18 years old, with T2DM for more than 1 year, HbA1c 7.0–10.0%, receiving basal and mealtime insulin (with 4–5 daily injections) for at least 6 months, and had not previously used Gla-300. Individuals were excluded if they were taking oral antihyperglycemic drugs (OADs) other than metformin or were receiving corticosteroids. Full inclusion and exclusion criteria are listed in the Supplementary Methods.
Anzeige
Study Endpoints
After the baseline visit, two further visits were scheduled by the physician during the first 6 months (months 3 and 6), with the possibility to plan two extra visits over an additional 6-month period (months 9 and 12). As this study was observational, visits were planned every 3 months according to the current clinical practice in Belgium. Additional visits were allowed if considered necessary by the investigator.
The primary endpoint was a change in the Diabetes Treatment Satisfaction Questionnaire status version (DTSQs) total score from baseline to month 6 in participants with T2DM treated with Gla-300 in routine care (see Supplementary Methods for details of DTSQs methodology). The primary objective was to demonstrate a change of at least 2 points in the DTSQs total score (baseline to month 6), which was deemed as a clinically relevant improvement.
Secondary endpoints included additional Patient-Reported Outcomes (PROs) such as the Diabetes Treatment Satisfaction Questionnaire change version (DTSQc); World Health Organization (WHO)-5 Well-Being Index; Hypoglycemia Fear Survey (HFS)-II; and Pittsburgh Sleep Quality Index (PSQI). See Supplementary Methods for the methodology regarding the secondary PRO analyses. Reasons for starting Gla-300 were also assessed. The study also examined mean changes in bodyweight, body mass index (BMI), HbA1c, and Gla-300 dose. The proportion of participants who continued Gla-300 therapy was also recorded.
Self-reported hypoglycemia (severe, symptomatic, confirmed [≤ 70 mg/dL and < 54 mg/dL]) was recorded according to time (nocturnal [between 00:00 and 05:59] and at any time of day [24 h]). Severe hypoglycemia was defined (per American Diabetes Association guidelines) as an event that required the assistance of another person to actively administer carbohydrates, glucagon, or to take other corrective actions [19].
Safety outcomes including adverse events (AEs), serious adverse events (SAEs), and adverse events of special interest (AESI) were recorded.
Data Analysis and Statistics
The sample size calculation performed prior to the study (paired t test with nQuery Advisor Version 7.0) determined that the recruitment of 82 patients was required to detect a clinically relevant change of at least 2 points in the DTSQs total treatment satisfaction score at month 6 versus baseline (p value set at 0.05, standard deviation [SD] of 5.50, power of 90%). Taking into account an approximate 20% participant dropout rate, it was estimated that 100 patients should be enrolled to achieve the expected 82 completed patients at month 6.
The primary endpoint was assessed in the intent-to-treat (ITT) population (all individuals eligible for Gla-300 treatment at baseline) and in the per-protocol (PP) population (all participants who completed the study). Secondary efficacy endpoints were assessed in the ITT population. All endpoints were summarized by descriptive statistics. The primary endpoint was analyzed using a paired Student’s t test with p < 0.05 considered statistically significant. The normality of continuous secondary endpoints was assessed using Kolmogorov–Smirnov testing. For endpoints with more than two time points, mixed models were used, while changes from baseline were assessed with a one-sample t test. If normality was not achieved, Friedman’s testing was used for outcomes with more than two time points, and paired Wilcoxon’s testing was performed on outcomes with two time points. Statistical analysis was performed using IBM SPSS Statistics (Version 21.0) and StatXact (Version 6.0). Missing values were not replaced/extrapolated.
Results
Participant Disposition
The study was conducted between 2 June 2016 and 28 August 2018. Participant disposition is presented in Fig. 1. As the aim of this observational study was to be as close to real life as possible, data are presented primarily from the ITT population of 87 individuals, which included all those who received the allocated intervention. In total, 68 individuals completed the primary study and were included in the PP population; 67 patients completed the 6-month study extension period.
Fig. 1
Participant disposition in MAGE. AE adverse event, ITT intent-to-treat, PP per-protocol, T1DM type 1 diabetes
×
Anzeige
Baseline Characteristics
Baseline characteristics (ITT population) are presented in Table 1. The cohort was composed of people with T2DM with a mean (SD) BMI of 32 (5.5) kg/m2, mean age of approximately 64 (8.9) years, and diabetes duration of 17 (7.7) years. Approximately one-third of this cohort had microvascular complications and most participants had hypertension, as well as dyslipidemia. Prior to switching to Gla-300, most participants received Gla-100 as their basal insulin (85.1%) and insulin aspart as prandial insulin (62.1%). Gla-300 was prescribed with the main objectives of decreasing HbA1c (in 89.7%) and reducing hypoglycemic events (in 35.6%). Other objectives included reduced insulin volume (in 6.7%), weight loss (in 4.4%), increased flexibility (in 3.3%), and better glycemic stability (in 3.3%). At least one concomitant medication was taken by all participants, including metformin and statins in 77% and 79% of participants, respectively.
Table 1
Baseline characteristics (ITT population)
Parameter
Baseline characteristics
N (missing)
Mean ± SD
n (%)
Mean age, years
87 (0)
63.8 ± 8.9
–
Male gender
87 (0)
–
58 (66.7)
Mean diabetes duration, years
87 (0)
17.1 ± 7.7
–
Weight, kg
87 (0)
94.0 ± 18.1
–
BMI, kg/m2
87 (0)
32.2 ± 5.5
–
HbA1c, %
87 (0)
7.9 ± 0.6
–
Comorbidities
Retinopathy
–
28 (32.2)
Neuropathy
–
27 (31.0)
Nephropathy
–
30 (34.5)
Hypertension
–
73 (83.9)
Peripheral vascular disease
–
15 (17.2)
Atrial fibrillation
–
5 (5.7)
Transient ischemic attack
87 (0)
–
3 (3.4)
Stroke
–
4 (4.6)
Heart failure
–
7 (8.0)
Angina pectoris
–
9 (10.3)
Myocardial infarction
–
12 (13.8)
Hyperlipidemia/hypercholesterolemia
–
77 (88.5)
Family history of stroke/coronary disease
–
26 (29.9)
Diabetic foot
–
6 (6.9)
Previous basal insulin
Gla-100
–
74 (85.1)
Detemir
87 (0)
–
8 (9.2)
Isophane
–
5 (5.7)
Previous basal insulin dose, IU
Gla-100
74 (0)
35.5 ± 18.0
–
Detemir
8 (0)
54.8 ± 26.5
–
Isophane
5 (0)
47.6 ± 23.2
–
Mean baseline Gla-300 dose, IU
87 (0)
38.6 ± 19.0
–
Previous prandial insulin
Glulisine
–
18 (20.7)
Lispro
87 (0)
–
11 (12.6)
Aspart
–
54 (62.1)
Human
–
4 (4.6)
Previous prandial insulin dose, IU
Glulisine
18 (0)
39.8 ± 20.9
–
Lispro
11 (0)
48.3 ± 25.3
–
Aspart
54 (0)
44.1 ± 16.8
–
Human
4 (0)
40.0 ± 10.7
–
BMI body mass index, Gla-100 insulin glargine 100 U/mL, Gla-300 insulin glargine 300 U/mL, HbA1c glycated hemoglobin, SD standard deviation
Primary Endpoint
A mean (SD) improvement of 2.80 (5.46) points in the DTSQs total score between baseline and month 6 was achieved in the ITT population (p < 0.0001), meeting the primary objective of the study (improvement of at least 2 points) and the primary endpoint (DTSQs total score improvement). A similar improvement (2.69 [5.42]; p < 0.001) was achieved in the PP population, and in both the ITT and PP populations the significance of the DTSQs total score improvements was confirmed using paired Wilcoxon’s tests (p < 0.0001). A sensitivity analysis of the PP population, excluding two participants who received another diabetes drug (liraglutide, a glucagon-like peptide 1 receptor agonist), showed equivalent results (DTSQs improvement 2.67 [5.45] points). Improvement in DTSQs of at least 2 points between baseline and month 12 was also achieved in both the ITT population (DTSQs improvement [SD] 2.10 [5.50] points, p = 0.004) and the PP population (DTSQs improvement [SD] 2.10 [5.51] points, p = 0.004).
Secondary Endpoints
Patient-Reported Outcomes
The DTSQs total satisfaction score significantly improved between baseline and month 12 (Table 2; p = 0.004). Changes in perceived hypoglycemia between baseline and month 6 were also significant (− 0.41, p = 0.013). Changes in the DTSQc from baseline in total treatment satisfaction score at month 6, perceived hyperglycemia score at months 6 and 12, and perceived hypoglycemia score at months 6 and 12 were significantly improved (Table 2; p < 0.05).
Table 2
Change in patient-reported outcomes between baseline and months 6 and 12 (ITT population)
Patient-reported outcome
N
Mean
SD
p value
Valid
Missing
DTSQs
Change in total DTSQs score
Month 6 (primary endpoint)
69
17
2.80
5.46
< 0.0001
Month 12
62
24
2.10
5.50
0.004
Change in perceived hyperglycemia score
Month 6
69
17
– 0.45
2.05
NS
Month 12
62
24
– 0.27
1.90
NS
Change in perceived hypoglycemia score
Month 6
69
17
– 0.41
1.31
0.013
Month 12
62
24
– 0.08
1.63
NS
DTSQc
Change in satisfaction with treatment
Month 6
68
1
11.28
6.11
0.032
Month 12
63
6
11.00
5.71
NS
Change in perceived hyperglycemia score
Month 6
68
1
0.59
1.55
0.011
Month 12
63
6
0.51
1.66
0.003
Change in perceived hypoglycemia score
Month 6
68
1
0.15
1.46
0.001
Month 12
63
6
– 0.25
1.59
0.002
HFS-II
Change in behavior score
Month 6
67
19
– 2.38
7.39
0.010
Month 12
62
24
– 3.30
9.58
0.009
Change in worry score
Month 6
68
18
– 4.41
11.22
0.002
Month 12
63
23
– 4.80
12.33
0.003
Change in total score
Month 6
67
19
– 6.96
15.11
< 0.0001
Month 12
62
24
– 8.50
18.68
0.001
PSQI
Change in score
Month 6
68
18
– 0.73
2.94
0.044
Month 12
63
23
– 0.25
3.06
NS
DTSQc Diabetes Treatment Satisfaction Questionnaire change version, DTSQs Diabetes Treatment Satisfaction Questionnaire status version, HFS-II Hypoglycemia Fear Survey-II, ITT intent-to-treat, NS not significant (p > 0.05), PSQI Pittsburgh Sleep Quality Index, SD standard deviation
Changes in the WHO-5 Well-Being Index between baseline and months 6 (− 1.12) and 12 (3.17) did not achieve significance (p = 0.560 and p = 0.076, respectively). By contrast, significant changes in HFS-II behavior (− 2.38 and − 3.30, at 6 and 12 months, respectively), worry (− 4.41 and − 4.80, at 6 and 12 months, respectively), and total (− 6.96 and − 8.50 at 6 and 12 months, respectively) scores were observed (Table 2; p < 0.05). Sleep quality was significantly improved between baseline and month 6 (− 0.73, Table 2; p < 0.05).
HbA1c
The mean (SD) baseline HbA1c was 7.9 (0.6) %. Changes in HbA1c from baseline to month 6 (0.0%, p = 0.856) and month 12 (− 0.1%, p = 0.594) were not significant. However, more participants reached HbA1c < 7% at month 12 versus baseline (11.5% versus 0%).
Bodyweight and Gla-300 Dose
The mean (SD) baseline bodyweight was 94.0 (18.1) kg. Bodyweight changes between baseline and months 6 and 12 (0.47 kg and 0.34 kg, respectively) were not significant (p > 0.05). At baseline, the mean BI and Gla-300 doses were 38.0 IU and 38.6 IU, respectively. The mean Gla-300 dose increased by 7.9% (3.0 IU) at month 6 and 14.2% (5.5 IU) at month 12 (p < 0.0001 for both time points). There were no significant changes in the total prandial insulin doses from baseline to month 12 (p > 0.05).
Hypoglycemic Events
Participants experienced a mean of 21 self-reported hypoglycemic events per participant-year, of which two were nocturnal (Table 3). Most events (n = 17) required countermeasures and were symptomatic (n = 19). Seven events per participant-year were confirmed with a blood glucose reading of below 54 mg/dL (< 3.0 mmol/L) and fewer than one event per participant-year was classified as severe.
Table 3
Hypoglycemic events (ITT population)
Hypoglycemic events
N
Mean events per participant-year ± SD
Valid
Missing
Total
82
0
20.9 ± 41.0
Requiring counter measures
82
0
17.4 ± 38.8
Symptomatic
82
0
18.7 ± 39.7
Nocturnal (00:00 to 05:59)
78
4
2.3 ± 5.2
Confirmed ≤ 70 mg/dL
81
1
21.0 ± 41.1
Confirmed < 54 mg/dL
81
1
6.6 ± 17.5
Severe
82
0
0.2 ± 0.7
ITT intent-to-treat, SD standard deviation
Adverse Events
In total, 150 AEs were reported by 55 participants (63.2%). The most frequent non-hypoglycemic AEs were diarrhea (4.6%), bronchitis (4.6%), and myalgia (3.2%). Hypoglycemia was reported as an AE in 9.2% of participants; this should be considered an underestimation given that 49 participants (56% of the ITT population) reported at least one event in the hypoglycemia section of the electronic case report form. Two participants (2.3%) reported AEs considered related to Gla-300 by the investigator: arthralgia (n = 1) and myalgia (n = 2). Twelve participants (13.8%) reported 18 SAEs, with each type of SAE reported by only one participant; none were considered related to Gla-300 treatment. There was no reported AESI.
Discussion
Participants in MAGE are representative of people with T2DM typically followed in second-line diabetes clinics; however, the mean HbA1c value at baseline was slightly higher than reported for the general Belgian population [20], and all participants in MAGE were on basal-bolus insulin regimens, suggesting that the MAGE population in this study was at a more advanced stage of diabetes. Approximately one-third of participants had microvascular complications, as expected in a population of people who have long-term T2DM.
Anzeige
In this real-world population, switching to Gla-300 was associated with a significant improvement in treatment satisfaction at 6 and 12 months (2.8 points [p < 0.0001] and 2.1 points [p = 0.004], respectively); these improvements are in line with those reported in the EDITION 1 RCT (2.3 points from baseline to month 6) [8]. It is worth noting that the MAGE study evaluated fewer participants over 6 months than planned on the basis of power calculations. However, because the amplitude of the observed difference in treatment satisfaction between baseline and month 6 was greater than the estimated 2 points, power for the primary endpoint remained above 90%. Different approaches have been used to determine minimally important differences (MID) in QoL measures. An empirical method based on a systematic review of 38 studies suggests using a cutoff of half of the SD [21]. Hence, for the 7-point DTSQs scale, the MID should likely be approximately 3.5. A second group suggests a more stringent MID of 0.3 SD (i.e., a 2.1-point difference on the 7-point DTSQs scale) [22]. Of note, the baseline DTSQs score was 27.93 points on a scale of 36 points, suggesting an already high treatment satisfaction prior to switching.
One of the main drawbacks of DTSQs is the “ceiling” effect, as individuals tend to score their current baseline treatment satisfaction at a high level, possibly precluding further improvements by the end of the study [23]. The DTSQc was developed to overcome this bias by asking individuals to compare their new treatment versus their old treatment by the end of the trial. DTSQc results confirmed those from the DTSQs as they also showed a significant improvement in treatment satisfaction. Additionally, DTSQc identified significant improvements in both perceived frequency of hyperglycemia and hypoglycemia at both 6 and 12 months, suggesting improved perception of glucose control with the new treatment. This may be linked to a more stable glycemic profile when treated with Gla-300, compared with older BIs [5, 6, 24].
Improvement in treatment satisfaction scores may potentially be biased, as participants may be tempted to answer PRO questionnaires positively. However, as no improvements were observed in the other non–diabetes-specific QoL measures (such as the WHO-5 Well-Being Index measure), one may conclude that this bias was avoided in MAGE. This is in accordance with another real-world observational study of Gla-300 in adults with T2DM, which demonstrated a non-significant improvement in the non–diabetes-specific WHO-5 measure, alongside a significant improvement in the Diabetes Medication System Rating Questionnaire measure [15].
Gla-300 was associated with significant improvements in hypoglycemia fear scores (HFS-II total scores were in the range of MID: 2.0–5.8 or 3.6–3.9, depending on the methodology) [25]. Reductions in the hypoglycemia behavior and worry subscales also suggested participants were less likely to adopt damaging behaviors (e.g., insulin dose reduction or deliberately maintaining hyperglycemia during social events/important tasks), or have hypoglycemia-related worries (e.g., failing to recognize low blood glucose, losing control, or public embarrassment) [26]. Sleep quality improved between baseline and month 6, which may also be associated with improved QoL [27].
Anzeige
The overall annualized hypoglycemia rate in MAGE was comparable to that seen in EDITION 1 for Gla-300 (21 versus 26 events per participant-year, respectively), as was the rate of severe events (0.2 versus 0.3 events per participant-year) [8]. Comparing other categories of hypoglycemia between these two studies is confounded by different definitions, but the rates of hypoglycemia confirmed at either the ≤ 70 mg/dL or < 54 mg/dL thresholds in MAGE (21 and 6.6 events per participant-year, respectively) also appear similar to the rates seen in EDITION 1 for hypoglycemia, defined as “confirmed” (≤ 70 mg/dL or < 54 mg/dL) or “severe” (25 and 3.8 events per participant-year, respectively). Although this latter definition in EDITION 1 includes severe events, these were rare and so would not have a substantial impact on the rates reported; any differences may be due to differences in study design (real-world study versus RCT with treat-to-target approach, in EDITION 1). The frequency of overall AEs was low in this study, and the most commonly experienced non-hypoglycemic AEs of diarrhea, bronchitis, and myalgia are in line with those reported in the 6-month EDITION 1 study, where the most common AEs in both treatment groups were infections, gastrointestinal events, or musculoskeletal complaints [8].
Improvements in treatment satisfaction and reduction in hypoglycemia fear occurred without reduction in HbA1c between baseline and months 6 or 12. This is in agreement with other studies using DTSQs, which showed that, while improvements in treatment satisfaction were not associated with improved glycemic control, they were likely to improve treatment adherence and the perception individuals have about control of the disease [1]. Thus, improvements in treatment satisfaction may contribute to long-term stable glucose control.
There was an increase in Gla-300 dose between baseline and months 6 and 12 of up to 14%, which is in line with the EDITION trial program [8]. However, an insulin dose increase has not been seen in all studies [28, 29]. In this study, the dose increase occurred in parallel with clinically relevant benefits in PROs, such as increased treatment satisfaction and reduced hypoglycemia fear.
A strength of the MAGE study is the length of the study; the 6-month extension period confirmed the positive diabetes-specific PRO results from the 6-month study period. When interpreting the results of MAGE, consideration should be given to the open-label, non-interventional design of the study. Although the results are in accordance with the EDITION 1 RCT, they should be considered as complementary to the RCT data and deserve to be confirmed by additional trials. It is possible that the participants of MAGE may have decided to switch to Gla-300 as a result of dissatisfaction with their prior insulin therapy, which could have biased their perception of treatment satisfaction in favor of Gla-300. As individuals were unblinded and aware that they were receiving a “newer” and more advanced insulin, they may have been influenced to be more positive in treatment satisfaction and QoL scoring. However, the MAGE cohort appeared typical of those who attend second-line outpatient clinics, and the absence of improvement in non–diabetes-specific measures (e.g., WHO-5 Well-Being Index) makes a bias in favor of Gla-300 unlikely. Other limitations include the limited participant numbers, and the absence of a control group; however, this is reflective of the nature of this real-world study.
Conclusion
In a real-world population of people with advanced T2DM and comorbidities, the inclusion of Gla-300 as part of their basal-bolus insulin regimen resulted in clinically relevant improvements in treatment satisfaction and reduced hypoglycemia fear.
Acknowledgements
The authors thank the study participants, the trial staff, particularly Elke Meyssen and Frank Stessens, and the investigators for their participation.
Funding
The study was sponsored by Sanofi Belgium. Sanofi was involved in designing the trials, conducted the trials, and analyzed the data. The Diabetes Therapy Rapid Service Fee was also funded by Sanofi.
Medical Writing Assistance
Editorial assistance was provided by Vicky Hinstridge, B. Pharm, and Jennina Taylor-Wells, PhD, of Fishawack Communications Ltd, funded by Sanofi.
Authorship
All authors had full access to all the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.
Disclosures
Ides M. Colin has received an honorarium from Sanofi and is a member of the advisory board and/or speakers bureau at Sanofi. Kathy Alexandre is a Sanofi employee. Jacques Bruhwyler is an external contractor for data management, biostatistics, and medical writing. André Scheen is a member of the advisory board and/or speakers bureau at Sanofi. A.V., Novo Nordisk, Eli Lilly, Merck, AstraZeneca, and Boehringer Ingelheim. Ann Verhaegen has received an honorarium from Sanofi and is a member of the advisory board and/or speakers bureau at Sanofi, Novo Nordisk, Eli Lilly, Amgen, Merck, and Boehringer Ingelheim.
Compliance with Ethics Guidelines
MAGE was performed in accordance with the principles of the 18th World Medical Assembly (Declaration of Helsinki, 1964) and all subsequent amendments, the European guidelines for Good Epidemiology Practice, and complied with local regulatory requirements. The study was approved by Comité d’éthique hospital-facultaire universitaire de Liège (707) under reference number 2016–114. All participants signed an informed consent form before taking part in the study and study extension.
Data Availability
Qualified researchers may request access to patient-level data and related study documents, including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient-level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi’s data sharing criteria, eligible studies, and process for requesting access can be found at https://www.clinicalstudydatarequest.com.
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/
Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.
Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.
Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.
Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.
Update Innere Medizin
Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.
